腹腔胃肠道恶性肿瘤术后联合化疗的临床研究及运用

Clinical research and practice on the combined chemotherapy after the abdominal cavity gastro-intestinal tract malignant tumor operation

目的研究腹腔胃肠道恶性肿瘤术后腹腔、淋巴、静脉联合化疗较传统静脉化疗的优势。方法比较6年来腹腔胃肠道恶性肿瘤患者根治术后进行腹腔、淋巴、静脉联合化疗(共136名)的复发率、生存率的差异。结果腹腔胃肠道恶性肿瘤术后腹腔、淋巴、静脉联合化疗组患者1、2、3年无瘤生存率分别为83.6%、75.2%和69.3%,疗效明显优于静脉化疗组的1、2、3年无瘤生存率66.7%、54.2%和46.3%(P<0.05),两组3年腹腔内肿瘤复发率分别为23.5%和40.7%,差异具有显著性(P<0.01)。结论作为胃肠道恶性肿瘤根治术后辅助化疗方法,腹腔、淋巴、静脉联合化疗优于单一静脉化疗,对于减少腹腔内恶性肿瘤内复发有显著效果。

Objective To research on advantages of the combined chemotherapy of the abdominal cavity, lymph and the vein compare with the traditional vein chemotherapy after the abdominal cavity gastre - intestinal tract malignant tumor operation. Methods Compare the last six years＇ statistics of recurrence rate and survival rate of the patients who had taken the combined chemotherapy of the abdominal cavity, lymph and the vein after the abdominal cavity gastro -intestinal tract malignant tumor radical operation. Results After the combined chemotherapy of the abdominal cavity, lymph and the vein, the first three years＇ Disease Free Survival （DFS） of the patients are respectively 83.6%, 75.2% and 69.3% , which is obviously of greater curative effect compare with the vein chemotherapy group whose DFS are 66. 7%, 54.2% and 46. 3% （ P 〈 0. 05 ）. Within three years, the recurrence rate of the two groups of tumor are respectively 23.5% and 40. 7%, the difference is significant （ P 〈 0.01 ）. Conclusion As a supporting chemotherapy after the gastro - intestinal tract malignant tumor radi- cal operation, the combined chemotherapy of the abdominal cavity, lymph and the vein is better than the single vein chemotherapy, which has prominent effect on reducing the recrudescence of the malignant tumor in the abdominal cavity.